Getting arthritis gene therapy into the clinic.
Gene transfer technologies enable the controlled, targeted and sustained expression of gene products at precise anatomical locations, such as the joint. In this way, they offer the potential for more-effective, less-expensive treatments of joint diseases with fewer extra-articular adverse effects. A large body of preclinical data confirms the utility of intra-articular gene therapy in animal models of rheumatoid arthritis and osteoarthritis. However, relatively few clinical trials have been conducted, only one of which has completed phase II. This article summarizes the status in 2010 of the clinical development of gene therapy for arthritis, identifies certain constraints to progress and suggests possible solutions.
Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, RN-115, Boston, MA 02215, USA. cevans@bidmc.harvard.edu
Christopher H
CH
Evans
Steven C
SC
Ghivizzani
Paul D
PD
Robbins
D001172:Arthritis, Rheumatoid / Q000235:genetics / Q000628:therapy*; D002986:Clinical Trials as Topic; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D010003:Osteoarthritis / Q000235:genetics / Q000628:therapy*; D012219:Rheumatology / Q000379:methods*